Related Experiment Video
Updated: May 3, 2026

Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice
Published on: October 19, 2013
Pulmonary hypertension in extremely low birth weight infants: characteristics and outcomes
Wambui Waruingi1, Maroun Jean Mhanna
1Department of Pediatrics, Division of Neonatology, Metro Health Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, 44109, USA.
Insights
Pulmonary arterial hypertension (PAH) in extremely low birth weight (ELBW) infants is linked to maternal drug use and severe lung disease. These infants face higher mortality rates and prolonged ventilation needs.
Area of Science:
- Neonatal Medicine
- Pediatric Cardiology
- Respiratory Medicine
Background:
- Pulmonary arterial hypertension (PAH) is a serious condition affecting infants.
- Extremely low birth weight (ELBW) infants are particularly vulnerable to respiratory complications.
- Understanding PAH in ELBW infants is crucial for improving outcomes.
Purpose of the Study:
- To investigate the characteristics of pulmonary arterial hypertension (PAH) in extremely low birth weight (ELBW) infants.
- To determine the outcomes associated with PAH in this vulnerable population.
Main Methods:
- A retrospective case-control study was conducted.
- Data from ELBW infants admitted to a level III NICU between 2003 and 2010 were analyzed.
- Infants diagnosed with PAH were matched with control infants.
Main Results:
- PAH was diagnosed in 6.4% of ELBW infants.
- Infants with PAH were smaller at birth and had higher rates of maternal illicit drug exposure.
- PAH was associated with longer mechanical ventilation, severe bronchopulmonary dysplasia, and increased NICU mortality.
Conclusions:
- PAH in ELBW infants is associated with maternal illicit drug use.
- Prolonged mechanical ventilation and severe bronchopulmonary dysplasia are significant factors.
- PAH in ELBW infants leads to a substantial increase in early mortality.
Background:
To determine the characteristics and outcomes of pulmonary arterial hypertension (PAH) in extremely low birth weight (ELBW) infants.
Methods:
A retrospective case-control study of all ELBW infants admitted to a level III neonatal intensive care unit (NICU) between January 1, 2003 and December 31, 2010.
Results:
During the study period, 450 ELBW infants were admitted. 6.4% (29/450) were diagnosed with PAH and were matched to 26 controls. The mean gestational age of infants with PAH and their controls were similar [24.5 ± 1.3 vs. 24.9 ± 1.8 weeks (P=0.26)]; however the cases were smaller at birth than were controls [640.7 ± 119.5 vs. 727.0 ± 184.5 g (P=0.04)]. The diagnosis of PAH was made at a mean postnatal age of 131.8 ± 53.7 days. Infants with PAH had a higher rate of intrauterine exposure to illicit maternal drug use [12/29 (41%) vs. 1/25 (4%); P=0.001], a longer duration of initial mechanical ventilation [74.9 ± 28.3 vs. 59.1 ± 27.8 days; P=0.04)], a higher incidence of severe BPD [23/29 (79%) vs. 13/26 (50%); P=0.02], and a greater NICU mortality rate [12/29 (41%) vs. 4/26 (15%); P=0.04].
Conclusion:
PAH in ELBW infants is associated with maternal illicit drug use in pregnancy, longer exposure to mechanical ventilation, severe bronchopulmonary dysplasia and a significant increase in early mortality.
More Related Videos
08:08Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
06:15Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
Published on: March 6, 2019
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Pulmonary Embolism I: Introduction
Pulmonary Embolism I: Introduction
Pulmonary Cycle: Exhalation
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Pulmonary Edema II: Pathophysiology